GH Research (NASDAQ:GHRS) Shares Up 0.2% – Here’s What Happened

GH Research PLC (NASDAQ:GHRS)’s stock price traded up 0.2% during mid-day trading on Thursday . The stock traded as high as $9.70 and last traded at $9.26. 22,329 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 78,940 shares. The stock had previously closed at $9.24.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on GHRS shares. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Trading Down 4.2 %

The company has a market capitalization of $460.47 million, a price-to-earnings ratio of -13.82 and a beta of 0.74. The firm’s 50-day moving average price is $7.74 and its 200 day moving average price is $10.39.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. As a group, equities research analysts anticipate that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the period. GH Research accounts for 9.1% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 6th largest holding. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).